Year: 2004
Type: article
Abstract: Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the JCI documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 (see the related article beginning on page 475).What is an osteoclast?Osteoporosis always represents an imbalance in favor of osteoclast-mediated bone resorption relative to the bone-forming capacity of osteoblasts.In some conditions of accelerated skeletal loss, such as Paget disease, osteoclasts are greatly enlarged, which enhances the individual cell's resorptive activity.Most osteopenic disorders, however, develop as a consequence of accelerated bone degradation due to increased osteoclast number.Thus, inhibition of osteoclast formation by estrogen supplementation, or osteoclast function by bisphosphonate administration, has been the most effective means of arresting pathological bone loss.However, both forms of therapy are not without drawbacks, and new anti-resorptive targets are rapidly emerging.In this issue of the JCI, Ikeda et al. elegantly show that the JNK-1-activated c-Jun signaling pathway is key to osteoclastic bone resorption (1).The authors find that mice bearing a dominant-negative osteoclast-specific c-Jun transgene have impaired osteoclastogenesis and, because of failed bone resorption, develop increased bone mass in the form of osteopetrosis.Importantly, the failure of dominant-negative c-Jun transgenic mice to generate osteoclasts is due to arrested activation and expression of members of the nuclear factor of activated T cells (NFAT) family of transcription factors in osteoclast precursors.
DOI: 10.1172/jci22644
Author: Steven L. Teitelbaum
Institution: Washington University in St. Louis
Language: English
Topic: Bone Metabolism and Diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4243285955
